ANDROGEN RECEPTOR DEGRADATION ENHANCER PLATFORM
(ARD ENHANCERS)
|
Dermatology Clinical Indications |
Systemic Indications |
| |
|
It is widely known that the androgen receptor (AR) and androgens (male hormones) play critical and complex roles in the etiology of many different human diseases. These include several well-documented roles involving AR mediated changes in cellular function which impact prominent diseases in both men and women through impacting endocrine and metabolic, developmental, immunological, and neurological systems.
The therapeutic properties of ARD Enhancers are extensive in their therapeutic applications and consist of multiple dermatological and systemic based administration routes. Each of the clinical indications pursued represent disease states of considerable medical merit and impact health-related quality of life in terms of drastic physical, psychological, and economic consequences. Spanning from acne to cancer, the medicinal capacity of these novel small drug molecule candidates is immense and holds veritable promise in fulfilling unmet medical needs while also representing innovative drug development of immense commercial importance.
ASC’s androgen receptor degradation enhancer (ARD enhancer) drug development pipeline is categorized according to dermatological or systemic applications. Lead dermatological indications include the clinical stage acne and androgenetic alopecia (AGA) programs and a third topical indication in wound healing nearing completion of preclinical development. Systemic indications center on the orphan drug indication of Spinal Bulbar Muscular Atrophy (SBMA) or Kennedy’s Disease and is supported by an actively funded Cooperative Translational Research Grant of approximately $3mm under the auspices of the NINDS branch of the NIH. Additional systemic indications include oral or parenteral treatment of the prostate related conditions in including prostate cancer and benign prostatic hyperplasia (BPH). Other systemic applications in oncology using ARD enhancers consist of treatments for bladder cancer and HBV-induced hepatocellular carcinoma.
| TOP |
|